Weekly Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings

May 17, 2018 - By Nellie Rakes

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

Total analysts of 2 have positions in Collegium Pharmaceutical (NASDAQ:COLL) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 29, 2017 according to StockzIntelligence Inc Collegium Pharmaceutical has 6 analyst reports. In Monday, February 12 report Piper Jaffray maintained the stock with “Buy” rating. On Sunday, February 11 the firm has “Buy” rating given by Jefferies. On Thursday, December 14 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given by Piper Jaffray. On Thursday, December 7 the firm earned “Buy” rating by Piper Jaffray. On Tuesday, January 23 Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating. Piper Jaffray has “Buy” rating and $33.0 target. On Wednesday, November 29 Piper Jaffray maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with “Buy” rating. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

Ticker’s shares touched $25.1 during the last trading session after 2.20% change.Currently Collegium Pharmaceutical, Inc. is uptrending after 133.98% change in last May 17, 2017. COLL has 186,789 shares volume. COLL outperformed by 122.43% the S&P500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is worth $829.40 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news released recently go to: Nasdaq.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Why Depomed Inc.’s Shares Soared 23.2% Higher” released on May 10, 2018, “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018, “Collegium to Present at the Deutsche Bank Health Care Conference” with a publish date: May 02, 2018, “Collegium Pharmaceutical’s (COLL) CEO Michael Heffernan on Q1 2018 Results – Earnings Call Transcript” and the last “Collegium Reports First Quarter Financial Results and Provides Corporate Update” with publication date: May 09, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.